{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:15Z","timestamp":1792194915499,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R61NS130199"],"award-info":[{"award-number":["R61NS130199"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS100947"],"award-info":[{"award-number":["R01NS100947"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS136070"],"award-info":[{"award-number":["R21NS136070"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmc.2026.118640","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:21:35Z","timestamp":1774398095000},"page":"118640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Development of highly potent EP2 antagonists as novel anti-inflammatory neuroprotectants"],"prefix":"10.1016","volume":"138","author":[{"given":"Chenyao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Bee","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Bahraminejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118640_bb0005","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.prostaglandins.2009.04.003","article-title":"Emerging roles of PGE2 receptors in models of neurological disease","volume":"91","author":"Andreasson","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bmc.2026.118640_bb0010","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1021\/cr200010h","article-title":"Prostanoid receptors","volume":"111","author":"Hirata","year":"2011","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2026.118640_bb0015","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4155\/fmc-2023-0172","article-title":"Latest advancements in the study of the relationship between NSAIDs and three prostaglandin E2 synthases","volume":"15","author":"Ruan","year":"2023","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0020","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/bph.14622","article-title":"Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth","volume":"176","author":"Qiu","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2026.118640_bb0025","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/med.21744","article-title":"Small molecules targeting cyclooxygenase\/prostanoid cascade in experimental brain ischemia: do they translate?","volume":"41","author":"Jiang","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmc.2026.118640_bb0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/acsptsci.2c00241","article-title":"Novel, brain-permeable, cross-species benzothiazole inhibitors of microsomal prostaglandin E Synthase-1 (mPGES-1) dampen neuroinflammation in vitro and in vivo","volume":"6","author":"Sluter","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bmc.2026.118640_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/19420889.2023.2166237","article-title":"Prostaglandin production in brain endothelial cells during the initiation of fever","volume":"16","author":"Eskilsson","year":"2023","journal-title":"Commun Integr Biol"},{"key":"10.1016\/j.bmc.2026.118640_bb0040","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/15353702231179926","article-title":"The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders","volume":"248","author":"Sluter","year":"2023","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.bmc.2026.118640_bb0045","doi-asserted-by":"crossref","first-page":"8262","DOI":"10.1038\/s41467-025-63782-8","article-title":"Targeting prostaglandin E(2) receptor 2 in Schwann cells inhibits inflammatory pain but not inflammation","volume":"16","author":"Nassini","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118640_bb0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/01.STR.0000153797.33611.d8","article-title":"The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets","volume":"36","author":"Iadecola","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.bmc.2026.118640_bb0055","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1476-5381.2010.00715.x","article-title":"Prostaglandin signalling in cerebral ischaemia","volume":"160","author":"Andreasson","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2026.118640_bb0060","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1248\/bpb.34.1170","article-title":"Prostaglandin E2 and pain--an update","volume":"34","author":"Kawabata","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.bmc.2026.118640_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101682","article-title":"G protein-coupled receptors in acquired epilepsy: Druggability and translatability","volume":"183","author":"Yu","year":"2019","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bmc.2026.118640_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105238","article-title":"Prostaglandin E receptors as targets for ischemic stroke: novel evidence and molecular mechanisms of efficacy","volume":"163","author":"Li","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2026.118640_bb0075","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s13311-022-01191-1","article-title":"Inducible prostaglandin E synthase as a pharmacological target for ischemic stroke","volume":"19","author":"Li","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bmc.2026.118640_bb0080","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1111\/bph.16148","article-title":"Complementary roles of EP2 and EP4 receptors in malignant glioma","volume":"180","author":"Qiu","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2026.118640_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/mol.115.098202","article-title":"EP2 receptor Signaling regulates microglia death","volume":"88","author":"Fu","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bmc.2026.118640_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/14737175.2016.1134322","article-title":"Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus","volume":"16","author":"Du","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.bmc.2026.118640_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107504","article-title":"Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus","volume":"209","author":"Nagib","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmc.2026.118640_bb0100","doi-asserted-by":"crossref","first-page":"11816","DOI":"10.1021\/acs.jmedchem.1c00816","article-title":"EP2 antagonists (2011\u22122021): a decade\u2019s journey from discovery to therapeutics","volume":"64","author":"Sluter","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0105","doi-asserted-by":"crossref","first-page":"9313","DOI":"10.1021\/acs.jmedchem.3c00655","article-title":"Targeting EP2 receptor for drug discovery: strengths, weaknesses, opportunities, and threats (SWOT) analysis","volume":"66","author":"Ganesh","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-020-03160-0","article-title":"Restoring metabolism of myeloid cells reverses cognitive decline in ageing","volume":"590","author":"Minhas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118640_bb0115","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.apsb.2025.03.024","article-title":"Modulating inflammatory prostaglandin E2 signaling to mitigate neurobehavioral comorbidities associated with seizure disorders","volume":"15","author":"Jiang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2026.118640_bb0120","doi-asserted-by":"crossref","first-page":"10019","DOI":"10.1073\/pnas.1818544116","article-title":"PGE(2) signaling via the neuronal EP2 receptor increases injury in a model of cerebral ischemia","volume":"116","author":"Liu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2026.118640_bb0125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1021\/acsptsci.0c00040","article-title":"Inhibiting the PGE(2) receptor EP2 mitigates excitotoxicity and ischemic injury","volume":"3","author":"Li","year":"2020","journal-title":"ACS Pharmacol Transl Sci."},{"key":"10.1016\/j.bmc.2026.118640_bb0130","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1021\/acsptsci.4c00516","article-title":"Suppressing the inflammatory prostaglandin Signaling after thrombotic stroke ameliorates ischemic brain injury and facilitates poststroke recovery","volume":"7","author":"Jin","year":"2024","journal-title":"ACS Pharmacol Transl Sci."},{"key":"10.1016\/j.bmc.2026.118640_bb0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tips.2016.03.001","article-title":"Anti-inflammatory small molecules to treat seizures and epilepsy: from bench to bedside","volume":"37","author":"Dey","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmc.2026.118640_bb0140","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/j.1476-5381.2011.01495.x","article-title":"In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist","volume":"164","author":"af Forselles","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2026.118640_bb0145","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1073\/pnas.1120195109","article-title":"Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2","volume":"109","author":"Jiang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2026.118640_bb0150","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1021\/acs.jmedchem.5b00567","article-title":"A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques","volume":"58","author":"Fox","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129255","article-title":"The discovery of cyclic gamma-AApeptides as the promising ligands targeting EP2","volume":"87","author":"Gu","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118640_bb0160","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1073\/pnas.1218498110","article-title":"Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2026.118640_bb0165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuroscience.2014.08.050","article-title":"PGD2 DP1 receptor stimulation following stroke ameliorates cerebral blood flow and outcomes","volume":"279","author":"Ahmad","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.bmc.2026.118640_bb0170","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1021\/jm5000672","article-title":"Lead optimization studies of cinnamic amide EP2 antagonists","volume":"57","author":"Ganesh","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0175","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejmech.2014.05.076","article-title":"Development of second generation EP2 antagonists with high selectivity","volume":"82","author":"Ganesh","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0180","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1021\/acs.jmedchem.9b01218","article-title":"Potent, selective, water soluble, brain-permeable EP2 receptor antagonist for use in central nervous system disease models","volume":"63","author":"Amaradhi","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112646","article-title":"Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models","volume":"147","author":"Rawat","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2026.118640_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109356","article-title":"Preclinical development of an EP2 antagonist for post-seizure cognitive deficits","volume":"224","author":"Varvel","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmc.2026.118640_bb0195","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1038\/s44318-025-00611-0","article-title":"Structural insights into selective and dual antagonism of EP2 and EP4 prostaglandin receptors","volume":"44","author":"Wu","year":"2025","journal-title":"EMBO J"},{"key":"10.1016\/j.bmc.2026.118640_bb0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-4939-2152-2_15","article-title":"In vitro oxygen-glucose deprivation to study ischemic cell death","volume":"1254","author":"Tasca","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmc.2026.118640_bb0205","doi-asserted-by":"crossref","first-page":"9293","DOI":"10.1074\/jbc.M113.455816","article-title":"EP2 receptor signaling pathways regulate classical activation of microglia","volume":"288","author":"Quan","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0210","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/00498254.2022.2066581","article-title":"Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes","volume":"52","author":"Uehara","year":"2022","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bmc.2026.118640_bb0215","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/00498250110057350","article-title":"Utility of metabolic stability screening: comparison of in vitro and in vivo clearance","volume":"31","author":"Clarke","year":"2001","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bmc.2026.118640_bb0220","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acschemneuro.7b00486","article-title":"Discovery of 2-piperidinyl phenyl benzamides and trisubstituted pyrimidines as positive allosteric modulators of the prostaglandin receptor EP2","volume":"9","author":"Jiang","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmc.2026.118640_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111000","article-title":"Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma","volume":"39","author":"Hou","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmc.2026.118640_bb0230","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s12035-020-01923-4","article-title":"Inverse agonism of cannabinoid receptor type 2 confers anti-inflammatory and neuroprotective effects following status epilepticus","volume":"57","author":"Yu","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.bmc.2026.118640_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116645","article-title":"Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation","volume":"58","author":"Zhang","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118640_bb0240","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12974-022-02556-1","article-title":"Ablation of Siglec-E augments brain inflammation and ischemic injury","volume":"19","author":"Li","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.bmc.2026.118640_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41401-025-01743-z","article-title":"Status epilepticus-induced 12\/15-lipoxygenase drives neuroinflammation and contributes to neuronal injuries and behavioral comorbidities","author":"Rakib","year":"2026","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmc.2026.118640_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2025.102162","article-title":"New structural scaffolds to enhance the metabolic stability of arginine-derived PAD4 inhibitors","volume":"15","author":"Jia","year":"2025","journal-title":"Results Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626000969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626000969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:21:03Z","timestamp":1790281263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626000969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["S0968089626000969"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118640","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of highly potent EP2 antagonists as novel anti-inflammatory neuroprotectants","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118640"}}